The mitochondrial genome and mitochondrial muscle disorders

Current Opinion in Pharmacology

Volumn 1, Issue 3, 2001, Pages 288-293

  Schaefer, Andrew M ^a   Taylor, Robert W ^a   Turnbull, Douglass M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Genetics; Heteroplasmy; Mitochondrial DNA; Mitochondrial myopathies; Molecular Medicine; Mouse models; Pharmacology; Treatment

Indexed keywords

MITOCHONDRIAL DNA;

AGING; ANIMAL; DEGENERATIVE DISEASE; GENETICS; GENOME; HUMAN; MITOCHONDRIAL MYOPATHY; MUSCLE MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

AGING; ANIMALS; DNA, MITOCHONDRIAL; GENOME, HUMAN; HUMANS; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL MYOPATHIES; NEURODEGENERATIVE DISEASES;

EID: 0035380961     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00051-0     Document Type: Review

References (60)

1. Lightowlers R.N., Chinnery P.F., Howell N., Turnbull D.M. Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet. 13:1997;450-455.
2. Holt I., Harding A.E., Morgan-Hughes J.A. Deletion of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature. 331:1988;717-719.
3. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., Elsas L.J.D., Nikoskelainen E.K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 242:1988;1427-1430.
4. Servidei S. Mitochondrial encephalomyopathies: gene mutation. Neuromusc Disord. 11:2001;121-130. A complete and constantly updated list of the nuclear DNA and mtDNA mutations that have been reported to cause mitochondrial disease.
5. MITOMAP: a human mitochondrial genome database. Center for Molecular Medicine, Emory University, Atlanta, GA, USA. [See URL: http://www.gen.emory.edu/mitomap.html ].
6. Wallace D.C. Mitochondrial diseases in man and mouse. Science. 283:1999;1482-1488. A concise overview of mitochondrial genetics, mitochondrial disease in humans and the mouse models that have been created to study the molecular mechanisms causing pathology. Part of an excellent review issue of Science dedicated to mitochondria.
7. Melov S., Coskun P.E., Wallace D.C. Mouse models of mitochondrial disease, oxidative stress, and senescence. Mutat Res. 434:1999;233-242. A thorough review of mouse models of mitochondrial disease, with specific reference to the link between oxidative stress and mtDNA mutations.
8. Chinnery P.F., Turnbull D.M. Mitochondrial DNA and disease. Lancet. 54:1999;17-21. A comprehensive review of the role of mtDNA mutation in human disease. The paper describes the basic genetics, the heterogeneity of clinical presentation and the current strategies employed in the management of patients with mitochondrial disease.
9. Howell N. Human mitochondrial diseases: answering questions and questioning answers. Int Rev Cytol. 186:1999;49-107.
10. Shitara H., Hayashi J.I., Takahama S., Kaneda H., Yonekawa H. Maternal inheritance of mouse mtDNA in interspecific hybrids: segregation of the leaked paternal mtDNA followed by the prevention of subsequent paternal leakage. Genetics. 148:1998;851-857.
11. Poulton J., Macaulay V., Marchington D.R. Mitochondrial genetics '98: is the bottleneck cracked? Am J Hum Genet. 62:1998;752-757.
12. Chinnery P.F., Howell N., Lightowlers R.N., Turnbull D.M. Genetic counselling and prenatal diagnosis of mtDNA disease. Am J Hum Genet. 63:1998;1908-1911.
13. White S.L., Collins V.R., Wolfe R., Cleary M.A., Shanske S., DiMauro S., Dahl H.M., Thorburn D.R. Genetic counselling and prenatal diagnosis for the mitochondrial DNA mutations at Nucleotide 8993. Am J Hum Genet. 65:1999;474-482.
14. Chinnery P.F., Howell N., Lightowlers R.N., Turnbull D.M. MELAS and MERRF: the relationship between maternal mutation load and the frequency of affected offspring. Brain. 121:1998;1889-1894.
15. Shoffner J.M. Maternal inheritance and the evaluation of oxidative phosphorylation diseases. Lancet. 348:1999;1283-1288.
16. Larsson N.G., Clayton D.A. Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet. 29:1995;151-178.
17. Chomyn A., Martinuzzi A., Yoneda M., Daga A., Hurko O., Johns D., Lai S.T., Nonaka I., Angelini C., Attardi G. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci USA. 89:1992;4221-4225.
18. Lys mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibres (MERRF). Am J Hum Genet. 51:1992;1187-1200.
19. Leu(UUR) A3243G mutation in a MELAS pedigree. Ann Neurol. 47:2000;179-185.
20. Chinnery P.F., Taylor D.J., Brown D.T., Manners D., Styles P., Lodi R. very low levels of the mtDNA A3243G mutation associated with mitochondrial dysfunction in vivo. Ann Neurol. 47:2000;381-384. This paper, together with [19•], challenges the accepted view that states that high levels (greater than 85%) of mutant mtDNA are required to cause biochemical dysfunction, by demonstrating that very low levels of the A3243G MELAS mutation may have a profound effect on mitochondrial ATP production in vivo.
21. Schon E.A., Bonilla E., DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr. 29:1997;131-149.
22. Leu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 348:1990;651-653.
23. Lys mutation. Cell. 61:1990;931-937.
24. Chinnery P., Howell N., Lightowlers R., Turnbull D. Molecular pathology of MELAS and MERRF: the relationship between mutation load and clinical phenotype. Brain. 120:1997;1713-1721.
25. Chinnery P.F., Johnson M.A., Wardell T.M., Singh-Kler R., Hayes C., Brown D.T., Taylor R.W., Bindoff L.A., Turnbull D.M. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol. 48:2000;188-193. The authors present data for the minimum prevalence of mitochondrial disease and pathogenic mtDNA mutations based on referrals to a single neurology centre over the past decade.
26. Chinnery P.F., Howell N., Andrews R.A., Turnbull D.M. Clinical mitochondrial genetics. J Med Genet. 36:1999;425-436.
27. Jackson M.J., Schaefer J.A., Johnson M.A., Morris A.A.M., Turnbull D.M., Bindoff L.A. Presentation and clinical investigation of mitochondrial respiratory chain disease. Brain. 118:1995;339-357.
28. Moraes C.T., DiMauro S., Zeviani M., Lombes A., Shanske S., Miranda A.F., Nakase H., Bonilla E., Werneck L.C., Servidei S., et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. New Engl J Med. 320:1989;1293-1299.
29. Rotig A., Cormier V., Blanche S., Bonnefont J.P., Ledeist F. Pearson's marrow pancreas syndrome. A multisystem mitochondrial disorder of infancy. J Clin Invest. 86:1990;1601-1608.
30. DiMauro S., Schon E.A. Nuclear power and mitochondrial disease. Nat Genet. 19:1998;214-215.
31. Birch-Machin M.A., Taylor R.W., Cochran B., Ackrell B.A., Turnbull D.M. Late-onset optic atrophy, ataxia, and myopathy associated with a mutation of a complex II gene. Ann Neurol. 48:2000;330-335.
32. Nishino I., Spinazzola A., Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 283:1999;689-692. Having previously mapped the disease locus, the authors demonstrate that mutations in the thymidine phosphorylase (TP) gene located on chromosome 22 cause MNGIE, an autosomal recessive disorder characterised by multiple mtDNA deletions in skeletal muscle. Assay of TP activity in leukocytes from these patients showed severely decreased activities of the TP enzyme, raising the possibility that a disturbance of thymidine metabolism may contribute to abnormalities in mtDNA maintenance or replication.
33. Kaukonen J., Juselius J.K., Tiranti V., Kyttala A., Zeviani M., Comi G.P., Keranen S., Peltonen L., Suomalainen A. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 289:2000;782-785. This paper documents the identification of mutations in the nuclear gene encoding the heart and skeletal muscle isoform of ANT-1 in five families with autosomal dominant CPEO. These findings strongly support the role of ANT-1 in mtDNA maintenance.
34. Melov S., Shoffner J.M., Kaufman A., Wallace D.C. Marked increase in the number and variety of mitochondrial DNA. Nucleic Acids Res. 23:1995;4122-4126.
35. Brierley E.J., Johnson M.A., Lightowlers R.N., James O.F.W., Turnbull D.M. Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol. 43:1998;217-223.
36. Michikawa Y., Mazzucchelli F., Bresolin N., Scarlato G., Attardi G. Aging- dependent large accumulation of point mutations in the human mtDNA control region for replication. Science. 286:1999;774-779. The first demonstration of an age-dependent accumulation of large numbers of mtDNA point-mutations in human cells.
37. Chinnery P.F., Taylor G.A., Howell N., Brown D.T., Parsons T.J., Turnbull D.M. Point mutations of the mtDNA control region in normal and neurodegenerative human brains. Am J Hum Genet. 68:2001;529-532.
38. Ikebe S., Tanaka M., Ohno K., Sato W., Hattori K., Kondo T., Mizuno Y., Ozawa T. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun. 170:1990;1044-1048.
39. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., McKee A.C., Beal M.F., Graham B.H., Wallace D.C. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 23:1994;471-476.
40. Horton T.M., Graham B.H., Corral-Debrinski M., Shoffner J.M., Kaufman A.E., Beal M.F., Wallace D.C. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 45:1995;1879-1883.
41. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol. 48:2000;72-76.
42. Polyak K., Li Y., Zhu H., Lengauer C., Willson J.K., Markowitz S.D., Trush M.A., Kinzler K.W., Vogelstein B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 20:1998;291-293.
43. Fliss M.S., Usadel H., Caballero O.L., Wu L., Buta M.R., Eleff S.M., Jen J., Sidransky D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 287:2000;2017-2019.
44. Brenner C., Kroemer G. Mitochondria - the death signal integrators. Science. 289:2000;1150-1151.
45. Mirabella M., Di Giovanni S., Silvestri G., Tonali P., Servidei S. Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain. 123:2000;93-104. This paper is the first to investigate the possibility that muscle from patients with mitochondrial myopathies shows apoptotic features, and suggests that this process is integral to the pathogenesis of mitochondrial disorders.
46. Graham B.H., Waymire K.G., Cottrell B., Trounce I.A., MacGregor G.R., Wallace D.C. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet. 16:1997;226-234.
47. Melov S., Schneider J.A., Day B.J., Hinerfeld D., Coskun P., Mirra S.S., Crapo J.D., Wallace D.C. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet. 18:1998;159-163.
48. Larsson N.G., Wang J., Wihelmsson H., Oldfors A., Rustin P., Lewandoski M., Barsh G.S., Clayton D.A. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet. 18:1998;231-236.
49. Levy S.E., Waymire K.G., Kim Y.L., MacGregor G.R., Wallace D.C. Transfer of chloramphenicol-resistant mitochondrial DNA into the chimeric mouse. Transgenic Res. 8:1999;137-145.
50. Marchington D.R., Barlow D., Poulton J. Transmitochondrial mice carrying resistance to chloramphenicol on mitochondrial DNA: developing the first mouse model of mitochondrial DNA disease. Nat Med. 5:1999;957-960.
51. R mutation yielded animals with a range of phenotypes and ultrastructurally abnormal mitochondria.
52. Inoue K., Nakada K., Ogura A., Isobe K., Goto Y., Nonaka I., Hayashi J. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat Genet. 26:2000;176-181. Isolating mouse cybrid clones with high levels of a somatic mtDNA rearrangement, and fusing these with fertilised mouse eggs generated the elegant mouse model described in this paper. Mutant mtDNA (mtDNA duplication) was transmitted maternally, and accumulated to high levels causing mitochondrial dysfunction. The characteristic muscle histology observed closely parallels that seen in human disease, making this a most promising model for research.
53. Taylor R.W., Chinnery P.F., Clark K., Lightowlers R.N., Turnbull D.M. Treatment of mitochondrial disease. J Bioenerg Biomemb. 29:1997;195-205.
54. Kolesnikova O.A., Entelis N.S., Mireau H., Fox T.D., Martin R.P., Tarassov I.A. Suppression of mutations in mitochondrial DNA by tRNAs imported from the cytoplasm. Science. 289:2000;1931-1933. This paper investigates whether the tRNA import pathway can be used to complement respiratory chain deficiencies due to mtDNA mutations in human cells. The authors demonstrate that modified, cytoplasmic tRNAs can be specifically targeted to mitochondria and participate in mitochondrial translation.
55. Manfredi G., Gupta N., Vazquez-Memije M.E., Sadlock J.E., Spinazzola A., De Vivo D.C., Schon E.A. Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene. J Biol Chem. 274:1999;9386-9391.
56. Taylor R.W., Chinnery P.F., Turnbull D.M., Lightowlers R.N. Selective inhibition of mutant mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet. 15:1997;212-215.
57. Chinnery P.F., Taylor R.W., Diekert K., Lill R., Turnbull D.M., Lightowlers R.N. Peptide nucleic acid delivery to human mitochondria. Gene Therapy. 6:1999;1919-1928.
58. Clark K.M., Bindoff L.A., Lightowlers R.N., Andrews R.M., Griffiths P.G., Johnson M.A., Turnbull D.M. Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet. 16:1997;222-224.
59. Shoubridge E.A., Johns T., Karpati G. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum Mol Genet. 6:1997;2239-2242.
60. Leu(CUN) mutation. Following a four-week training protocol, a significant decrease in the proportion of COX-negative muscle fibres and an increase in the amount of wild-type to mutant mtDNAs were observed, highlighting the potential therapeutic benefits of this 'gene shifting' treatment strategy.